The SYNERGY trial: Study design and rationale

American Heart Journal

Volumn 143, Issue 6, 2002, Pages 952-960

  Mahaffey, Kenneth W ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW MOLECULAR WEIGHT HEPARIN; NITRIC ACID DERIVATIVE; TIROFIBAN;

ADULT; AGED; ARTICLE; CLINICAL OBSERVATION; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG SAFETY; EARLY DIAGNOSIS; FIBRINOLYTIC THERAPY; HEART INFARCTION; HEPARINIZATION; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; MULTICENTER STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; Q WAVE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; ST SEGMENT ELEVATION;

EID: 0036085758     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2002.122120     Document Type: Article

References (43)

1. The pathogenesis of coronary artery disease and the acute coronary syndromes
2. Shifting the open-artery hypothesis downstream: The quest for optimal reperfusion
3. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban
4. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study
5. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction
6. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes
7. Randomized, placebo-controlled trial of titrated intravenous lamifiban for acute coronary syndromes
8. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease
9. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: Results of the Thrombolysis In Myocardial Infarction (TIMI) 11B trial
10. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q wave myocardial infarction: TIMI 11B-ESSENCE meta-analysis
11. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease. One-year results of the ESSENCE study
12. Strategies of patient care in acute coronary syndromes: Rationale for the Global Registry of Acute Coronary Events (GRACE) registry
13. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: A meta-analysis
14. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II
15. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomised, placebo-controlled trial
16. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
17. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade
18. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction
19. Antithrombotic Combination Using Tirofiban and Enoxaparin: The ACUTE II study
20. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention
21. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
22. The use of enoxaparin and IIb/IIIa antagonists in acute coronary syndromes, including PCI: Final results of the NICE 3 study
23. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction
24. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction
25. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation
26. Misreporting of myocardial infarction end points: Results of adjudication by a central clinical events committee in the PARAGON-B trial
27. Disagreements between a central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: Review of the PURSUIT study
28. Systematic adjudication of myocardial infarction endpoints in an international clinical trial
29. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease
30. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2
31. A comparison of reteplase with alteplase for acute myocardial infarction
32. Myocardial infarction redefined - A consensus document of the joint European Society of Cardiology/ American College of Cardiology Committee for the redefinition of myocardial infarction
33. Association between minor elevations of creatine kinase-MB level and mortality in patients with acute coronary syndromes without ST-segment elevation
34. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making
35. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation: Results from an international trial of 9461 patients
36. Equivalence trials
37. Quality of care at teaching and nonteaching hospitals
38. Potential impact of evidence-based medicine in acute coronary syndromes: Insights from GUSTO-IIb
39. Do "America's Best Hospitals" perform better for acute myocardial infarction?
40. Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: Results from the ESSENCE randomized trial
41. Low molecular weight heparin therapy for percutaneous coronary intervention: A practice in evolution
42. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris